Cellectis (CLLS) Depreciation & Amortization (IS) (2015 - 2026)
Cellectis (CLLS) posted Depreciation & Amortization (IS) of $4.5 million for Q1 2026, down 9.5% on a QoQ basis from $5.0 million in Q3 2025, and down 8.03% year-over-year from $4.9 million in Q1 2025.
Cellectis (CLLS) has 12 years of Depreciation & Amortization (IS) data on file, last reported at $4.5 million in Q1 2026.
- In Q1 2026, Depreciation & Amortization (IS) fell 8.03% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $19.5 million (up 2.88% YoY), while the FY2022 annual figure was $11.7 million, up 53.89% from the prior year.
- Depreciation & Amortization (IS) eased to $4.5 million in Q1 2026, from $5.0 million in the prior quarter.
- Across five years, Depreciation & Amortization (IS) topped out at $15.0 million in Q3 2022 and bottomed at -$5.6 million in Q1 2022.
- A 5-year average of $3.4 million and a median of $4.6 million in 2024 frame the typical range for Depreciation & Amortization (IS).
- The widest YoY moves for Depreciation & Amortization (IS): up 244.19% in 2022, down 249.93% in 2022.
- Year by year, Depreciation & Amortization (IS) stood at $5.3 million in 2022, then dropped by 15.21% to $4.5 million in 2023, then advanced by 5.69% to $4.7 million in 2024, then grew by 6.17% to $5.0 million in 2025, then slipped by 9.5% to $4.5 million in 2026.
- The last three Depreciation & Amortization (IS) figures came in at $4.5 million (Q1 2026), $5.0 million (Q3 2025), and $5.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 127,436.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 12.00 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | 4.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.54 Mn |
| Sep 30, 2025 | 5.01 Mn |
| Jun 30, 2025 | 5.02 Mn |
| Mar 31, 2025 | 4.93 Mn |
| Sep 30, 2024 | 4.72 Mn |
| Jun 30, 2024 | 4.73 Mn |
| Mar 31, 2024 | 4.57 Mn |
| Sep 30, 2023 | 4.47 Mn |
| Jun 30, 2023 | -4.43 Mn |
| Mar 31, 2023 | -4.46 Mn |
| Dec 31, 2022 | 5.27 Mn |
| Sep 30, 2022 | 15.02 Mn |
| Jun 30, 2022 | -5.11 Mn |
| Mar 31, 2022 | 4.90 Mn |
| Dec 31, 2021 | 5.04 Mn |
| Sep 30, 2021 | 4.37 Mn |
| Jun 30, 2021 | 3.41 Mn |
| Mar 31, 2021 | 3.77 Mn |
| Dec 31, 2020 | 3.25 Mn |
| Sep 30, 2020 | 2.58 Mn |
| Jun 30, 2020 | 2.15 Mn |
| Mar 31, 2020 | 2.05 Mn |
| Dec 31, 2019 | 1.95 Mn |
| Sep 30, 2019 | 1.72 Mn |
| Jun 30, 2019 | 1.69 Mn |
| Mar 31, 2019 | -1.53 Mn |
| Sep 30, 2018 | 468,000.00 |
| Jun 30, 2018 | 633,000.00 |
| Mar 31, 2018 | 629,000.00 |
| Sep 30, 2017 | 683,000.00 |
| Jun 30, 2017 | -656,430.94 |
| Mar 31, 2017 | 633,000.00 |
| Sep 30, 2016 | 2.66 Mn |
| Jun 30, 2016 | -511,833.39 |
| Mar 31, 2016 | 526,136.82 |
| Dec 31, 2015 | 566,692.63 |
| Sep 30, 2015 | 499,415.92 |
| Jun 30, 2015 | 497,313.57 |
| Mar 31, 2015 | 371,714.89 |